IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

28 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

30 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

24 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022

18 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

18 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

10 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

24 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

18 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

11 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Immutep to Present at February Investor Conferences

31 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

25 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Immutep Advances IMP761 Manufacturing

16 Dec 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

02 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

19 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

15 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

15 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

09 Nov 2021 08:05:00 By Nasdaq GlobeNewswire

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

09 Nov 2021 08:00:04 By Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

02 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

29 Oct 2021 08:00:00 By Nasdaq GlobeNewswire